CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D008269: Macular Edema NIH

(Synonyms: Macular Edema)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug3320 life questionnaires Wiki 0.71
drug845 Data collection up to 1 year Wiki 0.71
drug3436 questionnaire Wiki 0.50
drug870 Dexamethasone Wiki 0.29
drug2311 Questionnaire Wiki 0.14

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D012170 Retinal Vein Occlusion NIH 0.71
D008268 Macular Degeneration NIH 0.50
D011111 Polymyalgia Rheumatica NIH 0.41
D013700 Giant Cell Arteritis NIH 0.41
D009103 Multiple Sclerosis NIH 0.20
D002908 Chronic Disease NIH 0.20

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0011505 Cystoid macular edema HPO 1.00
HP:0012636 Retinal vein occlusion HPO 0.71

There are 2 clinical trials

Clinical Trials


1 COVID-19 Related Lockdown Effects On Chronic Diseases

The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.

NCT04390126 Chronic Coronary Syndrome Heart Failure AMD and Macular Edema Chronic Respiratory Failure Hemophilia Malignant Hemopathy Multiple Sclerosis Horton's Disease Other: life questionnaires Other: questionnaire
MeSH:Polymyalgia Rheumatica Respiratory Insufficiency Multiple Sclerosis Giant Cell Arteritis Macular Edema Chronic Disease
HPO:Cystoid macular edema Macular edema

Primary Outcomes

Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)

Measure: % adherence to each pharmacological class

Time: during the period from 20 April 2020 to 7 May 2020

Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)

Measure: number of occurrence of medical events at 1 year

Time: throughout the study for 12 months

Secondary Outcomes

Description: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change

Measure: Expressed in %: Non-pharmacological treatment/lifestyle:

Time: during the period from 20 April 2020 to 7 May 2020

Measure: Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication

Time: during the period from 20 April 2020 to 7 May 2020

Measure: Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)

Time: during the period from 20 April 2020 to 7 May 2020

2 Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

NCT04395859 Age Related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion Procedure: Questionnaire Other: Data collection up to 1 year
MeSH:Macular Degeneration Macular Edema Retinal Vein Occlusion
HPO:Cystoid macular edema Macular edema Retinal vein occlusion

Primary Outcomes

Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up

Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic

Time: Baseline (Before confinement) and 6 months after resumption of follow-up


HPO Nodes